|Bid||7.00 x 1200|
|Ask||7.01 x 800|
|Day's Range||6.58 - 7.23|
|52 Week Range||1.55 - 19.39|
|Beta (5Y Monthly)||2.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
The biotech has multiple potential clinical readouts for its COVI-19 products in the months ahead, but investors should also keep an eye on the company's cash reserves.
Salicyn 30 is an antiviral that blocks infection of cells by the novel coronavirus. COVIDTRAP is an ACE2 receptor decoy, which could bind up the coronavirus and keep it from infecting cells. Brian Orelli: You've got a couple of other treatments that you're working on.
Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete. Brian Orelli: We talked about a lot of different products. Henry Ji: Brian, our company has a lot of expertise, especially the antibodies space.